Author

Federico Argüelles-Arias

EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Federico Argüelles-Arias  et al.

LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Federico Argüelles-Arias  et al.

TOFACITINIB IN ULCERATIVE COLITIS: SHORT TERM OUTCOMES IN REAL WORLD EXPERIENCE IN THE SOUTH OF SPAIN
TOFACITINIB IN ULCERATIVE COLITIS: SHORT TERM OUTCOMES IN REAL WORLD EXPERIENCE IN THE SOUTH OF SPAIN

Federico Argüelles-Arias  et al.

ANTI-INFLAMMATORY EFFECT OF MAQUI EXTRACT ON PPAR-Α EXPRESSION IN EPITHELIAL AND MACROPHAGE CELLS IN COLON TISSUE FROM EXPERIMENTAL MODEL OF CROHN’S DISEASE
ANTI-INFLAMMATORY EFFECT OF MAQUI EXTRACT ON PPAR-Α EXPRESSION IN EPITHELIAL AND MACROPHAGE CELLS IN COLON TISSUE FROM EXPERIMENTAL MODEL OF CROHN’S DISEASE

Federico Argüelles-Arias  et al.

COMPARISON OF TWO ANALYTICAL TECHNIQUES FOR QUANTIFYING INFLIXIMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARISON OF TWO ANALYTICAL TECHNIQUES FOR QUANTIFYING INFLIXIMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Federico Argüelles-Arias  et al.

INCIDENCE AND EVOLUTION OF SARS-COV2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SOUTHERN SPAIN (ANDALUSIA)
INCIDENCE AND EVOLUTION OF SARS-COV2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SOUTHERN SPAIN (ANDALUSIA)

Federico Argüelles-Arias  et al.

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Federico Argüelles-Arias  et al.

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU
INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

Federico Argüelles-Arias  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

Federico Argüelles-Arias  et al.

EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN’S DISEASE PATIENTS WITH INSUFFICIENT RESPONSE TO STANDARD-DOSE SUBCUTANEOUS MAINTENANCE THERAPY: AN OBSERVATIONAL MULTICENTRE STUDY
EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN’S DISEASE PATIENTS WITH INSUFFICIENT RESPONSE TO STANDARD-DOSE SUBCUTANEOUS MAINTENANCE THERAPY: AN OBSERVATIONAL MULTICENTRE STUDY

Federico Argüelles-Arias  et al.

Item 1 - 10 / 10
1